LCIS

LCIS is most often discovered incidentally — meaning it is found when a biopsy is performed for another reason, such as a suspicious area on a mammogram that turns out to be benign. The abnormal cells are confined to the lobules (the milk-producing glands) and do not form a lump or show distinctive signs on mammography. Because LCIS typically does not cause any symptoms and is not visible on standard imaging, it is usually identified only through tissue sampling.

The distinction between LCIS and DCIS (ductal carcinoma in situ) is clinically important. DCIS involves cells in the milk ducts that look cancer-like and carry a meaningful risk of progressing to invasive cancer in the same breast if left untreated; it is treated like a very early cancer. LCIS, by contrast, is now understood primarily as a risk indicator: it tells you that your breast tissue has a demonstrated tendency to develop abnormal cells, and that your risk of invasive breast cancer — in either breast — is elevated over a lifetime. Most women with LCIS will never develop invasive breast cancer.

Management of LCIS focuses on monitoring and risk reduction rather than aggressive treatment. Most women are followed with regular clinical exams and mammography; MRI screening may be added for higher-risk cases. Risk-reduction medications such as tamoxifen or raloxifene can significantly lower the risk of future invasive breast cancer for women with LCIS, and your provider can discuss whether they are appropriate for you based on your overall risk profile.

An LCIS finding can feel alarming, especially when you hear the word 'carcinoma.' Understanding that LCIS is a risk marker rather than a cancer — and that most women with LCIS do not go on to develop invasive breast cancer — can help you approach the conversation with your provider more calmly and with better questions.

The most important thing you can do after an LCIS diagnosis is stay engaged with your follow-up plan. That means keeping your screening appointments, discussing your overall breast cancer risk with your provider (including any family history and genetic factors), and having an honest conversation about whether risk-reduction medication makes sense for you. LCIS is also a reason to know your breast density and whether additional imaging such as breast MRI would be appropriate. Knowledge and consistent monitoring are your most effective tools.